Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
ADC Therapeutics raises big money for drug conjugates
by Michael McCoy
October 24, 2016
| A version of this story appeared in
Volume 94, Issue 42
ADC Therapeutics, a Swiss developer of antibody-drug conjugates for cancer, has raised $105 million from new and existing investors including AstraZeneca, Auven Therapeutics, and the Wild Family Office. ADC’s drugs use antibodies to deliver pyrrolobenzodiazepine-based warheads to both solid tumors and hematological malignancies. ADC says it has raised $255 million since its inception in 2012. Two of its drugs, ADCT-301 and ADCT-402, are in clinical studies against lymphoma and leukemia. Its next two drug candidates will target solid tumors.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X